Deleted member 3129
90 iq at best
-
- Joined
- Jan 30, 2018
- Posts
- 5,012
What's the science behind this? Cba to look it up. Or is it mostly a stereotype?
Eliminating racial disparities in cancer screening, diagnosis, treatment and mortality is an essential step toward the improvement of health outcomes for all cancer patients in America1. The promise of this objective depends on identifying and addressing the multifactorial reasons underlying the disparities. It is well recognized that socioeconomic issues, such as income and treatment delays, play a critical role in the high mortality of several cancers in minority populations2. Meanwhile, some studies show that biological factors may contribute to these inequities, especially in disease incidence and patient survival3.
Previous studied have associated the race-related survival stratification of cancer patients to the differences of genetic alterations present in tumor cells. Carethers et al.4 showed that the frequency of microsatellite instability (MSI) among African American colon cancers is half of that of MSI for the Caucasian counterpart. The authors proposed that, because MSI is associated with good survival for colon cancer patients, the relative lack of MSI in African American patients could be related to the high morality. Keenan et al.5 reported that racial differences in TP53 mutation, PAM50 basal subtype and triple-negative tumor prevalence influence the magnitude and significance of racial disparity in tumor recurrence of breast cancer. Petrovics et al.6 observed distinct prevalence between African American (AA) and Caucasian American prostate cancer (CaP) genomes in three recurrent genomic alterations, which occurred in the genes (loci) PTEN, LSAMP region and ERG. They further found that a novel deletion of the LSAMP locus, as a prevalent genomic alteration in AA CaP, was associated with rapid disease progression.
In this study, we first used the data released by the Cancer Genome Atlas (TCGA) to estimate the effect of race on patient survival time and mutation burden of tumors in 16 cancer types (subtypes). Then, we extended the analysis to the determination of potential relationship between mutation burden and disease incidence, a less investigated issue, by integrating TCGA data and the data from the Surveillance, Epidemiology, and End Results (SEER) Program. The results obtained from this study enrich our knowledge in cancer disparities and the related carcinogenic process.
ah basedHigher standard of living and access to medicine, therefore lower child mortality and higher chances of maladaptive mutations
This is sufficient, I hope:
Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate
The causes underlying racial disparities in cancer are multifactorial. In addition to socioeconomic issues, biological factors may contribute to these inequities, especially in disease incidence and patient survival. To date, there have been few studies ...www.ncbi.nlm.nih.gov